Atsena Raises $150M to Advance Gene Therapy for Inherited Blindness

Published on Spencer Knight via LinkedIn

Atsena Therapeutics has secured an oversubscribed $150 million Series C round, led by Bain Capital, to support development of its ocular gene therapy platform. The lead candidate, ATSN-201, targets X-linked retinoschisis (XLRS), a rare and currently untreatable genetic cause of blindness.

Their Lighthouse trial is already in Phase 1/2, with more clinical data expected soon. Spencer Knight notes that this level of investor enthusiasm signals continued confidence in gene therapy not just as a treatment, but as a curative platform for rare ophthalmic diseases.

Read the full post on LinkedIn:

👉 Spencer Knight: Atsena Raises $150M to Fight Blindness

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.